OUR SOLUTION APPROACH AGAINST SARS-CoV-2

IML-206 as a broad-spectrum antiviral drug for the treatment of patients infected with SARS-CoV-2 or other (future) coronaviruses. Unlike many other developments, the innovative substance IML-206 blocks specific cellular structures in humans, which are very likely indispensable for the replication of a broad range of coronavirus variants.


OUR SOLUTION APPROACH AGAINST HIV RESISTANCES

IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.

ImmunoLogik GmbH

Org chart

Teams

Similar companies